Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study

Fig. 2

DAPSA subgroups responses to Upadacitinib in the UPREAL-PsA study. DAPSA (Disease Activity in Psoriatic Arthritis) in the UPREAL-PsA (Upadacitinib therapy in the real-life in patients with psoriatic arthritis) study at week 12 (w12) and 24 (w24) in different patients’ subgroups: Bio-Naïve and Bio-Failure: naïve to or treated with biological drugs; AxPsA and PerPsA: axial (prevalent) or peripheral inflammation; Poli and Oligo: polyarticular or oligoarticular involvement; PsO: Psoriasis; Norm-CRP vs High-CRP: C-Reactive Protein normal or upper the normal limit (0.05 mg/dl); High- vs normal-BMI: body mass index > 30 o < 30, respectively; CVD: cardiovascular diseases; MTB: metabolic diseases. Statistical analisys was performed between DAPSA at week 12 and baseline and between DAPSA at week 24 and week 12. Statistical analysis was conducted by “Stata” software (Paired Student’s t test). Statistical significance: n.s.: not significant; p: < 0.05*, < 0.01**, < 0.001***, < 0.0001****

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us